These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35365779)

  • 1. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.
    Jiang S; Mathias PC; Hendrix N; Shirts BH; Tarczy-Hornoch P; Veenstra D; Malone D; Devine B
    Pharmacogenomics J; 2022 May; 22(3):188-197. PubMed ID: 35365779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
    Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
    Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
    Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
    Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
    Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.
    You JH
    Pharmacogenomics; 2015; 16(10):1089-100. PubMed ID: 26230572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
    Eckman MH; Rosand J; Greenberg SM; Gage BF
    Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
    Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
    Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
    Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
    Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
    Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
    Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
    Okere AN; Ezendu K; Berthe A; Diaby V
    J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.